Lumir

Akanda’s CanMart Subsidiary to Distribute Award-Winning Cannim Cannabis Products to UK Patients

Retrieved on: 
Dienstag, November 16, 2021
Alternative Medicine, Retail, Health, Other Retail, Agriculture, Natural Resources, Specialty, Darkness, GMP, Pharmacy, GACP, Health, CEO, Knowledge, Good manufacturing practice, Lumir, Good, Research, Kingdom, Partnership, Carbon, Akanda, Disclosure, ESG, DNA Genetics, Farm, Wellness, Cannabis, Patient, Drug, Akanda Corp., Cannim, AKANDA CORP., CANNIM

Akanda Corp. ("Akanda" or the Company) today announced that its wholly-owned subsidiary, CanMart Ltd. (CanMart), has entered into a distribution agreement with Australia-based Cannim to bring the award-winning Lumir range of medical cannabis products to UK patients.

Key Points: 
  • Akanda Corp. ("Akanda" or the Company) today announced that its wholly-owned subsidiary, CanMart Ltd. (CanMart), has entered into a distribution agreement with Australia-based Cannim to bring the award-winning Lumir range of medical cannabis products to UK patients.
  • CanMart will import and distribute Cannims full-spectrum medical cannabis oil products over a five-year agreement.
  • Cannim satisfies the Australian market with an award-winning Lumir CBD50 which was recently recognised as CBD Product of the Year at the Australian Cannabis Industry Awards.
  • Patients in the UK will now have access to Cannims high-quality Jamaica-grown medical cannabis products for the first time, said Tej Virk, CEO and Director of Akanda.

Cantourage brings the first medical cannabis flowers from Jamaica to the European market via its Fast Track Access Platform

Retrieved on: 
Donnerstag, August 19, 2021
Good, Good manufacturing practice, Farm, Lumir, Research, Pharmacy, Darkness, Health, Pharmacopoeia, Multimedia, Patient, Partnership, Dronabinol, Light, GMP, Drug

Cannim will sell its products in the EU medical markets through the Cantourage Fast Track Access Platform.

Key Points: 
  • Cannim will sell its products in the EU medical markets through the Cantourage Fast Track Access Platform.
  • The agreement allows medical cannabis flowers from Jamaica to be made available to German patients for the first time.
  • Philip Schetter, Co-CEO of Cantourage comments: "We are delighted to offer patients in Germany this unprecedented opportunity by bringing medical cannabis from Jamaica into the fast-growing European medical cannabis market for the first time.
  • After the introduction of medical cannabis from Uruguay, Cannim's Jamaican Lumir is the second medical cannabis product entering the European market through the Fast Track Access Platform.

Cantourage brings the first medical cannabis flowers from Jamaica to the European market via its Fast Track Access Platform

Retrieved on: 
Donnerstag, August 19, 2021
Good, Good manufacturing practice, Farm, Lumir, Research, Pharmacy, Darkness, Health, Pharmacopoeia, Patient, Partnership, Dronabinol, Light, GMP, Drug

BERLIN, Aug. 19, 2021 /PRNewswire/ -- Cantourage, one of Europe's leading providers of medical cannabis, has today launched its offering of high-quality medical cannabis flowers from Jamaica in Germany. Cantourage has successfully partnered with Australian-based Cannim, the leading cultivator of medicinal cannabis in Jamaica. Cannim will sell its products in the EU medical markets through the Cantourage Fast Track Access Platform. The agreement allows medical cannabis flowers from Jamaica to be made available to German patients for the first time.

Key Points: 
  • Cannim will sell its products in the EU medical markets through the Cantourage Fast Track Access Platform.
  • The agreement allows medical cannabis flowers from Jamaica to be made available to German patients for the first time.
  • Philip Schetter, Co-CEO of Cantourage comments: "We are delighted to offer patients in Germany this unprecedented opportunity by bringing medical cannabis from Jamaica into the fast-growing European medical cannabis market for the first time.
  • After the introduction of medical cannabis from Uruguay, Cannim's Jamaican Lumir is the second medical cannabis product entering the European market through the Fast Track Access Platform.